NCT00380692

Atomoxetine Versus Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents With Autism Spectrum Disorder

A Randomized, Double-blind Comparison of Atomoxetine Hydrochloride and Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents With Autism Spectrum Disorder

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 97 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 6 Years – 17 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether atomoxetine is effective in reducing ADHD (Attention Deficit/Hyperactivity Disorder) symptoms in children and adolescents with ASD (Autism Spectrum Disorder).

Conditions

• Autistic Disorder
• Attention Deficit Disorder With Hyperactivity

Interventions

Type	Name	Description
DRUG	Atomoxetine
DRUG	Placebo

Timeline

• Start date: 2006-10-01
• Primary completion: 2008-05-01
• Completion: 2008-10-01
• First posted: 2006-09-26
• Last updated: 2010-05-11
• Results posted: 2009-07-08

Locations

8 sites across 1 country: Netherlands